• The NWHN’s statement on the results of the Evidence for Contraceptive Options and HIV trial (ECHO)
    June 14, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. The National Women’s Health Network (The NWHN) is pleased that the results of the ECHO trial provide reassuring evidence that Depo Provera does NOT significantly increase the risk of HIV infection when compared to ...
  • The NWHN’s statement on the FDA ordering manufacturers of surgical mesh to stop selling devices for uterine prolapse
    April 16, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240   The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington, D.C. — Today, the U.S. Food and Drug Administration ordered the manufacturers of all remaining surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse (POP) to stop selling and ...
  • The NWHN’s statement on the FDA ordering Sprout Pharmaceuticals to retain black box label warning women not mix Addyi and alcohol
    April 12, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C. —  Yesterday the U.S. Food and Drug Administration ordered Sprout Pharmaceuticals to update the label of their female libido pill, flibanserin (brand name: Addyi). The label change says women should ...
  • The NWHN’s statement in response to FDA approving Evenity
    April 10, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org  Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C.- Yesterday, the US Food and Drug Administration approved a new treatment romosozumab, brand name Evenity, from drugmakers Amgen and UCB for osteoporosis in postmenopausal women who are at high risk ...
  • The NWHN advises women to be cautious about using flibanserin until new studies are fully vetted
    March 26, 2019
      The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. WASHINGTON D.C. — Women should not use flibanserin or any drug unless they have sufficient information to weigh benefits against risks. Sprout Pharmaceuticals’ new alcohol studies should be reviewed with a healthy skepticism, until they have been vetted ...
  • NWHN statement in response to the FDA’s action against Aid Access
    March 12, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C.- In a letter released Tuesday, the FDA warned online abortion pill provider AidAccess.org to immediately stop importing mifepristone and misoprostol, the two drugs that make up the most ...
  • The NWHN’s statement on the resignation of FDA Commissioner Scott Gottlieb 
    March 5, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org  Telephone: (202) 682-6240  The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.  Washington D.C.- Today, US Food and Drug Administration Commissioner Scott Gottlieb announced his plan to leave the FDA in about a month.   Prior to his confirmation, the NWHN raised concerns about Gottlieb’s approach to women’s health, his close ties to the pharmaceutical industry, and ...
  • The NWHN’s Statement on Title X Rule Release
    February 22, 2019
    For Immediate Release Contact: Evita Almassi, ealmassi@nwhn.org The following statement can be attributed to Sarah Christopherson, Policy Advocacy Director at the National Women’s Health Network Washington, D.C. –   Today, the Trump-Pence administration is once again attacking women’s reproductive health. Last year, HHS rushed through a proposed rule to gut Title X, the country’s only domestic family planning grant ...
  • NWHN Statement on FDA’s decision on Generic Drug Labels
    December 13, 2018
    For Immediate Release Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington, DC — Today the U.S. Food and Drug Administration (FDA) announced their decision to withdraw the proposed rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological ...
  • NWHN calls for Kavanaugh to withdraw nomination
    September 24, 2018
    For Immediate Release Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-2640 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.   Washington, DC — Yesterday, a second accuser bravely came forward with disturbing allegations of sexual assault by Supreme Court nominee, Brett Kavanaugh. Today, news reports suggest that there may be ...